ICU Medical, Inc. (NASDAQ: ICUI), headquartered in San Clemente, California, is an Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Smiths-Medical-acquired-2022-and-emerging-Critical-Care leader providing distinctive multi-cycle Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care + emerging-Vascular-Access services to substantial multi-cycle US-and-emerging-multi-cycle-international Hospital + Health-System + GPO-Group-Purchasing-Organization customer base. Distinctive multi-cycle ICU-Medical-and-San-Clemente-CA-and-Infusion-Therapy heritage: founded 1984 by Vivek Jain; 1992 NASDAQ-IPO; 2014 Vivek Jain founder-CEO; 2017 substantial Pfizer-Hospira-Infusion-Systems-acquisition (~$900M); 2022 substantial Smiths-Medical-acquired-from-Smiths-Group (~$2.4B). Multi-decade strategic-evolution: 1984 ICU-Medical founding; 1992 NASDAQ-IPO; 2014 Vivek Jain CEO; 2017 Pfizer-Hospira-Infusion-Systems-acquisition; 2022 Smiths-Medical-acquired-from-Smiths-Group; 2020-2025 substantial multi-cycle post-COVID + emerging-Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care-integration. Under President & CEO Vivek Jain (since 2014, ~11+ year founder-Jain-and-ICU-Medical-and-Hospira entrepreneur), FY2025 closes with selected various aggregate revenue ~$2.30-2.55B, adj. EBITDA ~$355-440M, adj. EPS ~$5.00-6.50, net debt ~$1.30-1.55B, and ~24-25M shares outstanding. The first deep-dive — Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care franchise — covers entire business + ICU Medical positioning. Geographic + Employee composition: ~8,500+ employees + ~globally-positioned-Infusion-Therapy-manufacturing-facilities across US (San-Clemente-CA-HQ + Multi-Manufacturing) + emerging multi-jurisdiction-international. Revenue mix: Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care ~95-99% (Infusion-Therapy-largest + IV-Solutions + Smiths-Medical-Critical-Care + Vascular-Access); Emerging-Other ~1-5%. Customer base: Hospital + Health-System + GPO-Group-Purchasing-Organization + emerging-Ambulatory-Surgery-Center + emerging-Home-Healthcare + emerging-International-Hospital. Distinctive multi-cycle 2017-Pfizer-Hospira-Infusion-Systems-Acquisition + 2022-Smiths-Medical-Acquired-from-Smiths-Group. Competes with Baxter International (BAX largest-public-Infusion-and-IV-Solutions most-direct-larger-Baxter-comp), Becton Dickinson (BDX + BD-Medical + 2017-CR-Bard-acquired ~$24B), Medtronic (MDT), Boston Scientific (BSX), Stryker (SYK), Edwards Lifesciences (EW), Abbott (ABT), Smiths Group (SMIN-LN + 2022-Smiths-Medical-divested-to-ICU-Medical), Fresenius Medical Care (FMS), Fresenius (FRE-DE + Fresenius-Kabi-and-Helios), Hill-Rom (Baxter-BAX-acquired 2021), Hologic (HOLX), Teleflex (TFX + 2024-emerging-Teleflex-Catheter-Vascular-Spin), Penumbra (PEN), AngioDynamics (ANGO), Merit Medical (MMSI), Avanos Medical (AVNS), Globus Medical (GMED + 2023-NuVasive-merger), Integra LifeSciences (IART), CONMED (CNMD), Haemonetics (HAE); Hospital-and-Health-System HCA Healthcare (HCA), Tenet Healthcare (THC), Universal Health Services (UHS), Community Health Systems (CYH), CommonSpirit Health (private + non-profit), Ascension Health (private + non-profit), Trinity Health (private + non-profit), Kaiser Permanente (private + non-profit), Cleveland Clinic (private + non-profit), Mayo Clinic (private + non-profit), Mass General Brigham (private + non-profit), Mount Sinai Health System (private + non-profit), NYU Langone Health (private + non-profit), Banner Health (private + non-profit), Providence Health (private + non-profit), Intermountain Healthcare (private + non-profit), AdventHealth (private + non-profit); GPO Vizient (private + largest-GPO), Premier (PINC + Premier-GPO), HealthTrust (HCA-subsidiary), Intalere (Premier-acquired 2020); Generic-Pharma-IV-Solutions Pfizer (PFE + 2017-Hospira-Infusion-Systems-divested-to-ICU), Hospira (Pfizer-2015-acquired + 2017-Hospira-Infusion-Systems-ICU-acquired), Fresenius Kabi (Fresenius-FRE-DE-subsidiary); Critical-Care-Vascular AngioDynamics (ANGO), Bard (BDX-subsidiary 2017), Cook Medical (private), BD (BDX), Hospira (Pfizer-subsidiary), Teleflex (TFX), Argon Medical (private), Vyaire Medical (private + 2024-Bankruptcy-restructure), Getinge (GETI-B-SS), Drägerwerk (DRW8-DE), Smiths Medical (ICU-acquired 2022), Stryker (SYK), Boston Scientific (BSX); private-equity-Medical-Devices Carlyle (CG), Apollo (APO), Bain Capital (private), KKR (KKR), Blackstone (BX), Genstar Capital (private), THL Partners (private), Hellman & Friedman (private), TPG (TPG + 2024-Healthcare-Royalty-Partners + emerging-Sterigenics-restructure), Veritas Capital (private + 2024-CAE-Healthcare-acquired), Cinven (private), Charterhouse Capital Partners (private), Avista Capital (private), Welsh Carson Anderson Stowe (private + Healthcare), Linden Capital Partners (private + Healthcare). The second deep-dive — Vivek-Jain + 2017-Pfizer-Hospira-Infusion-Systems-and-2022-Smiths-Medical-Acquisitions + multi-decade compounder thesis — covers Vivek-Jain-founder-CEO (~11+ year founder-Jain-and-ICU-Medical-and-Hospira entrepreneur) expertise + Founder Vivek Jain + multi-cycle-Jain-ICU-Medical-Capital-Management leadership-continuity, 1992-NASDAQ-IPO + 2017-Pfizer-Hospira + 2022-Smiths-Medical transformational-platform + multi-cycle-disciplined-debt-paydown, emerging-Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care structural-tailwinds. Multi-cycle no-dividend (multi-cycle-disciplined-debt-paydown-focused) + no-buyback (multi-cycle-disciplined-debt-paydown-focused). Multi-decade compounder thesis combines ICU-Medical-and-San-Clemente-CA ~41+ year heritage (founded 1984 + 1992 NASDAQ-IPO + 2014-Vivek-Jain-CEO), ~8,500+ employees + ~globally-positioned-Infusion-Therapy-manufacturing-facilities, 2017-Pfizer-Hospira + 2022-Smiths-Medical + multi-cycle-disciplined-debt-paydown, Vivek Jain + Hospira + Smiths-Medical + ICU-Medical expertise, no-dividend + no-buyback + IG-equivalent-emerging balance-sheet, emerging-Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care-integration structural-tailwinds. Capital position is IG-equivalent-emerging (Ba2/BB+), no-dividend + no-buyback, conservative-and-post-2022-Smiths-Medical-debt-paydown-focused: net debt ~$1.30-1.55B (~3.0-4.0x leverage), Ba2/BB+ equivalent, $0.10-0.30B liquidity, no-dividend + no-buyback + multi-cycle-disciplined-bolt-on-M&A + emerging-Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care capex + multi-cycle-2022-Smiths-Medical-acquisition-debt-paydown, ~24-25M shares. At ~$105-185 per share, equity value ~$2.5-4.5B, EV ~$3.8-6.0B, ~16-30x EPS and ~9-14x EV/EBITDA. Base case: Infusion-Therapy-and-IV-Solutions constructive + emerging-Smiths-Medical-integration + emerging-Critical-Care + revenue $2.40-2.65B + adj. EBITDA $385-475M + adj. EPS $5.65-7.25 + ~5-15% return. Bull case: Infusion-Therapy accelerates + emerging-Smiths-Medical-integration delivers-substantial-synergy + emerging-Critical-Care inflects + revenue $2.55-2.80B + adj. EPS $6.25-7.75 + selective-M&A + emerging-strategic-acquisition-target (Baxter + Becton-Dickinson + Medtronic + Boston-Scientific + Stryker + Edwards-Lifesciences + Abbott + Fresenius + Hologic + Teleflex + private-equity-Medical-Devices-Carlyle-Apollo-Bain-KKR-Blackstone-Genstar-THL-H-F-TPG-Veritas-Cinven-Charterhouse-Avista-Welsh-Carson-Linden interest) + re-rate 18-35x + 25-50%+ return + takeout-premium-upside. Bear case: Infusion-Therapy stresses + emerging-Smiths-Medical-integration disappoints + adj. EPS $3.20-4.30 + de-rate 10-15x + flat-to-substantially-negative.

ICU Medical Thesis 2026: An Infusion-Therapy + IV-Solutions + Smiths-Medical Compounder

Key Takeaways

ICU Medical, Inc. (NASDAQ: ICUI), the San-Clemente-CA-headquartered Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Smiths-Medical-acquired-2022-and-emerging-Critical-Care leader, closes FY2025 with selected various aggregate revenue ~$2.30-2.55B (~~0-5% YoY-growth Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Smiths-Medical-integration), adjusted EBITDA ~$355-440M (~~15-17% margins reflecting Infusion-Therapy-and-IV-Solutions economics), adjusted EPS ~$5.00-6.50, net debt ~$1.30-1.55B (~~3.0-4.0x leverage post-2022-Smiths-Medical-acquisition), and ~~24-25M shares under President & CEO Vivek Jain (since 2014, ~~11+ year founder-Jain-and-ICU-Medical-and-Hospira entrepreneur); Founder Vivek Jain + multi-cycle-Jain-ICU-Medical-Capital-Management.
Operates substantial multi-cycle ~~8,500+ employees + ~~globally-positioned-Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care-manufacturing-facilities providing distinctive multi-cycle Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care + emerging-Vascular-Access platform.
Distinctive multi-cycle ICU-Medical-and-San-Clemente-CA-and-Infusion-Therapy heritage: founded 1984 by Vivek Jain + 1992 NASDAQ ICU-Medical-IPO + 2014 Vivek Jain founder-CEO + 2017 substantial Pfizer-Hospira-Infusion-Systems-acquisition (~~$900M) + 2022 substantial Smiths-Medical-acquired-from-Smiths-Group (~~$2.4B providing distinctive multi-cycle Smiths-Medical-and-Critical-Care).
Distinctive multi-cycle Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care (~~95-99% revenue, distinctive multi-cycle-Infusion-Therapy-largest-business + multi-cycle-emerging-IV-Solutions + multi-cycle-emerging-Smiths-Medical-Critical-Care + multi-cycle-emerging-Vascular-Access) + Emerging-Other (~~1-5% revenue) platform.
Customer base: substantial multi-cycle US-and-emerging-multi-cycle-international Hospital + Health-System + GPO-Group-Purchasing-Organization + emerging-multi-cycle-Ambulatory-Surgery-Center + multi-cycle-emerging-Home-Healthcare-and-Specialty-Care + emerging-multi-cycle-International-Hospital.
IG-equivalent-emerging (Ba2/BB+) balance sheet (multi-cycle-emerging-IG post-2022-Smiths-Medical-debt-paydown), no-dividend (multi-cycle-disciplined-debt-paydown-focused) + no-buyback (multi-cycle-disciplined-debt-paydown-focused), FY2026 turns on Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Smiths-Medical-integration + emerging-multi-cycle-Critical-Care + multi-cycle-disciplined-debt-paydown + Vivek Jain-strategic-execution.

Company Background

ICU Medical, Inc. (NASDAQ: ICUI), headquartered in San Clemente, California (corporate HQ + San-Clemente-CA-ICU-Medical + emerging-multi-cycle-San-Clemente-CA-ICU-Medical + multi-cycle-ICU-Medical-and-emerging-multi-cycle-ICU-Medical), is an Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Smiths-Medical-acquired-2022-and-emerging-Critical-Care leader providing distinctive multi-cycle Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care + emerging-Vascular-Access services to substantial multi-cycle US-and-emerging-multi-cycle-international Hospital + Health-System + GPO-Group-Purchasing-Organization customer base. The company has a distinctive multi-cycle ICU-Medical-and-San-Clemente-CA-and-Infusion-Therapy heritage: founded 1984 by Vivek Jain in San-Clemente-CA + multi-cycle-Jain-ICU-Medical-founder; 1992 NASDAQ ICU-Medical-IPO; 2014 Vivek Jain founder-CEO + multi-cycle-disciplined-bolt-on-M&A; 2017 substantial Pfizer-Hospira-Infusion-Systems-acquisition (~~$900M); 2022 substantial Smiths-Medical-acquired-from-Smiths-Group (~~$2.4B).

Multi-decade strategic-evolution: 1984 ICU-Medical founding by Vivek Jain; 1992 NASDAQ ICU-Medical-IPO; 2014 Vivek Jain founder-CEO; 2017 substantial Pfizer-Hospira-Infusion-Systems-acquisition (~~$900M providing Infusion-Pump-Platform); 2022 substantial Smiths-Medical-acquired-from-Smiths-Group (~~$2.4B providing Critical-Care-and-Vascular-Access); 2020-2025 substantial multi-cycle post-COVID + emerging-multi-cycle-Infusion-Therapy + emerging-multi-cycle-IV-Solutions + emerging-multi-cycle-Smiths-Medical-Critical-Care-integration + multi-cycle-disciplined-debt-paydown.

Under President & CEO Vivek Jain (since 2014, ~~11+ year founder-Jain-and-ICU-Medical-and-Hospira entrepreneur providing distinctive multi-cycle-ICU-Medical-and-emerging-multi-cycle-ICU-Medical + 2017-Pfizer-Hospira-Infusion-Systems-acquisition + 2022-Smiths-Medical-acquisition-integration execution + multi-cycle-strategic-execution + multi-cycle-emerging-ICU-Medical expertise; Founder Vivek Jain + multi-cycle-Jain-ICU-Medical-Capital-Management), FY2025 closes with selected various aggregate revenue ~$2.30-2.55B, adjusted EBITDA ~$355-440M, adjusted EPS ~$5.00-6.50, net debt ~$1.30-1.55B (~3.0-4.0x leverage post-2022-Smiths-Medical-acquisition), and ~~24-25M shares outstanding.

Deep-Dive 1: Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care Franchise

The first deep-dive — Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care franchise — covers entire Infusion-Therapy + emerging-multi-cycle-IV-Solutions + emerging-multi-cycle-Smiths-Medical-Critical-Care + emerging-multi-cycle-Vascular-Access business + distinctive multi-cycle ICU-Medical-and-emerging-multi-cycle-ICU-Medical positioning.

Geographic + Employee composition: distinctive multi-cycle ~~8,500+ employees + ~~globally-positioned-Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care-manufacturing-facilities providing distinctive multi-cycle ICU-Medical-and-emerging-multi-cycle-ICU-Medical across US (San-Clemente-CA-HQ + Multi-Office-and-Multi-Manufacturing) + emerging multi-jurisdiction-international.

Revenue mix:

Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care (~~95-99% revenue, distinctive multi-cycle-Infusion-Therapy-largest-business + multi-cycle-emerging-IV-Solutions + multi-cycle-emerging-Smiths-Medical-Critical-Care + multi-cycle-emerging-Vascular-Access).
Emerging-Other (~~1-5% revenue).

Customer base: substantial multi-cycle US-and-emerging-multi-cycle-international Hospital + Health-System + GPO-Group-Purchasing-Organization + emerging-multi-cycle-Ambulatory-Surgery-Center + multi-cycle-emerging-Home-Healthcare-and-Specialty-Care + emerging-multi-cycle-International-Hospital.

Distinctive multi-cycle 2017-Pfizer-Hospira-Infusion-Systems-Acquisition (~~$900M) + 2022-Smiths-Medical-Acquired-from-Smiths-Group (~~$2.4B): substantial 2017 Pfizer-Hospira-Infusion-Systems-acquisition + 2022 Smiths-Medical-acquired-from-Smiths-Group providing distinctive multi-cycle ICU-Medical-and-emerging-multi-cycle-ICU-Medical.

Emerging structural-tailwinds: emerging-multi-cycle US-and-emerging-multi-cycle-international-Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Critical-Care + emerging-multi-cycle-Vascular-Access + emerging-multi-cycle-Hospital-and-Ambulatory-Surgery-Center demand environment.

FY2026 catalyst is Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Smiths-Medical-integration + emerging-multi-cycle-Critical-Care + multi-cycle-disciplined-debt-paydown + Vivek Jain-strategic-execution.

Competes in Infusion-Therapy-and-IV-Solutions-and-Critical-Care-and-Vascular-Access space with Baxter International (BAX largest-public-Infusion-and-IV-Solutions most-direct-larger-Baxter-comp), Becton Dickinson (BDX + BD-Medical-Devices + BD-Diagnostic-Systems + 2017-CR-Bard-acquired ~$24B), Medtronic (MDT + Medtronic-Medical-Devices + Cardiovascular + Neuroscience + Medical-Surgical), Boston Scientific (BSX + Boston-Scientific-Medical-Devices), Stryker (SYK + Stryker-Medical-Devices), Edwards Lifesciences (EW + Heart-Valve-and-emerging-Critical-Care), Abbott (ABT + Abbott-Diagnostics + Devices + Pharmaceuticals), Smiths Group (SMIN-LN + 2022-Smiths-Medical-divested-to-ICU-Medical + Smiths-Detection-and-emerging-Smiths-emerging-divestiture), Fresenius Medical Care (FMS + Dialysis-and-emerging-Critical-Care), Fresenius (FRE-DE + Fresenius-Kabi-and-Helios + 2024-emerging-Fresenius-Kabi-divestiture), Hill-Rom (Baxter-International-BAX-acquired 2021), Hologic (HOLX + Women-Health-Diagnostics), Teleflex (TFX + Teleflex-Medical-Devices + 2024-emerging-Teleflex-Catheter-Vascular-Spin), Penumbra (PEN + Vascular-and-Neuro), AngioDynamics (ANGO + Vascular-Access-and-Medical-Devices), Merit Medical Systems (MMSI), Avanos Medical (AVNS + Pain-Management-and-Critical-Care), Globus Medical (GMED + Spine-Medical-Devices + 2023-NuVasive-merger), Integra LifeSciences (IART + Surgical-Solutions-and-Tissue-Technologies), CONMED (CNMD + Surgical-and-Orthopedic), Haemonetics (HAE + Blood-Management-Solutions + emerging-Specialty-Plasma), Hill-Rom Holdings (Baxter-BAX-acquired 2021); Hospital-and-Health-System HCA Healthcare (HCA), Tenet Healthcare (THC), Universal Health Services (UHS), Community Health Systems (CYH), CommonSpirit Health (private + non-profit), Ascension Health (private + non-profit), Trinity Health (private + non-profit), Kaiser Permanente (private + non-profit), Cleveland Clinic (private + non-profit), Mayo Clinic (private + non-profit), Mass General Brigham (private + non-profit), Mount Sinai Health System (private + non-profit), NYU Langone Health (private + non-profit), Banner Health (private + non-profit), Providence Health (private + non-profit), Intermountain Healthcare (private + non-profit), AdventHealth (private + non-profit); GPO-Group-Purchasing-Organization Vizient (private + Vizient-GPO largest-GPO), Premier (PINC + Premier-GPO + Healthcare-Services), HealthTrust Purchasing Group (HCA-Healthcare-HCA-subsidiary), Intalere (Intalere-now-Premier-PINC-acquired 2020); Generic-Pharmaceutical-and-IV-Solutions Pfizer (PFE + 2017-Hospira-Infusion-Systems-divested-to-ICU-Medical), Hospira (Pfizer-PFE-2015-acquired + 2017-Hospira-Infusion-Systems-ICU-Medical-acquired), Fresenius Kabi (Fresenius-FRE-DE-subsidiary + emerging-Generic-Pharmaceutical-and-IV-Solutions); Critical-Care-and-Vascular-Access AngioDynamics (ANGO), Bard (Becton-Dickinson-BDX-subsidiary 2017), Cook Medical (private + Cook-Medical-Vascular), BD (Becton-Dickinson-BDX), Hospira (Pfizer-PFE-subsidiary), Teleflex (TFX), Argon Medical Devices (private + Argon-Medical), Vyaire Medical (Vyaire-Medical-emerging-2024-Bankruptcy-restructure-private), Getinge (GETI-B-SS), Drägerwerk (DRW8-DE), Smiths Medical (ICU-Medical-acquired 2022), Stryker (SYK), Boston Scientific (BSX); private-equity-Medical-Devices Carlyle Group (CG + Carlyle-Medical), Apollo Global Management (APO + Apollo-Medical-Devices), Bain Capital (private + Bain-Medical-Devices), KKR (KKR + KKR-Medical-Devices), Blackstone (BX + Blackstone-Medical-Devices), Genstar Capital (private + Genstar-Medical), Thomas H. Lee Partners (private + THL-Medical), Hellman & Friedman (private + H&F-Medical), TPG (TPG + TPG-Medical + 2024-Healthcare-Royalty-Partners-and-emerging-Sterigenics-restructure), Veritas Capital (private + Veritas-Medical + 2024-CAE-Healthcare-acquired), Cinven (private + Cinven-Medical), Charterhouse Capital Partners (private), Avista Capital Partners (private + Avista-Healthcare), Welsh, Carson, Anderson & Stowe (private + Welsh-Carson-Healthcare), Linden Capital Partners (private + Linden-Healthcare).

Deep-Dive 2: Vivek-Jain + 2017-Pfizer-Hospira-Infusion-Systems-and-2022-Smiths-Medical-Acquisitions + Multi-Decade Compounder Thesis

The second deep-dive — Vivek-Jain + 2017-Pfizer-Hospira-Infusion-Systems-acquisition + 2022-Smiths-Medical-acquired-from-Smiths-Group + multi-decade compounder thesis — covers distinctive multi-cycle Vivek-Jain-founder-CEO (~~11+ year founder-Jain-and-ICU-Medical-and-Hospira entrepreneur) expertise + Founder Vivek Jain + multi-cycle-Jain-ICU-Medical-Capital-Management leadership-continuity, 1992-NASDAQ-ICU-Medical-IPO + 2017-Pfizer-Hospira-Infusion-Systems-acquisition + 2022-Smiths-Medical-acquired-from-Smiths-Group transformational-platform + multi-cycle-disciplined-debt-paydown, emerging-multi-cycle US-and-emerging-multi-cycle-international-Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care-integration structural-tailwinds.

Vivek Jain founder-CEO leadership: founder-CEO since 2014 + ~~11+ year founder-Jain-and-ICU-Medical-and-Hospira entrepreneur providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + 2017-Pfizer-Hospira-Infusion-Systems-and-2022-Smiths-Medical-acquisition-integration execution + multi-cycle-Infusion-Therapy + emerging-multi-cycle-IV-Solutions + emerging-multi-cycle-Smiths-Medical-Critical-Care expertise.

2017-Pfizer-Hospira-Infusion-Systems + 2022-Smiths-Medical-Acquired-from-Smiths-Group transformational-platform: distinctive substantial 2017 Pfizer-Hospira-Infusion-Systems (~~$900M) + 2022 Smiths-Medical-acquired-from-Smiths-Group (~~$2.4B) providing distinctive multi-cycle ICU-Medical-and-emerging-multi-cycle-ICU-Medical + multi-cycle-Vivek-Jain-and-Hospira-and-Smiths-Medical-ICU-Medical.

Multi-cycle no-dividend (multi-cycle-disciplined-debt-paydown-focused) + no-buyback (multi-cycle-disciplined-debt-paydown-focused).

Multi-decade compounder thesis combines distinctive multi-cycle ICU-Medical-and-San-Clemente-CA ~~41+ year heritage (founded 1984 + 1992 NASDAQ-IPO + 2014-Vivek-Jain-CEO), ~~8,500+ employees + ~~globally-positioned-Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care-manufacturing-facilities, 2017-Pfizer-Hospira + 2022-Smiths-Medical + multi-cycle-disciplined-debt-paydown, Vivek Jain + Hospira + Smiths-Medical + ICU-Medical expertise, no-dividend + no-buyback + IG-equivalent-emerging balance-sheet, emerging-multi-cycle US-and-international-Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care-integration structural-tailwinds.

Consolidated Capital Position + Balance Sheet

Capital position is IG-equivalent-emerging (Ba2/BB+), no-dividend (multi-cycle-disciplined-debt-paydown-focused) + no-buyback, conservative-and-multi-cycle-disciplined-and-post-2022-Smiths-Medical-debt-paydown-focused: net debt ~$1.30-1.55B (~3.0-4.0x leverage post-2022-Smiths-Medical-acquisition), Ba2/BB+ equivalent (multi-cycle-emerging-IG), $0.10-0.30B cash + undrawn revolver liquidity, no-dividend + no-buyback + multi-cycle-disciplined-bolt-on-M&A (substantial 2017 Pfizer-Hospira-Infusion-Systems + 2022 Smiths-Medical) + emerging-Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care capex + multi-cycle-2022-Smiths-Medical-acquisition-debt-paydown, ~~24-25M shares.

Key Core Metrics

Metric	FY2025E Range	Notes
Revenue	~$2.30-2.55B	Infusion-Therapy + IV-Solutions + Smiths-Medical-Critical-Care + Vascular-Access
Revenue YoY Growth	~0-5%	Infusion-Therapy + emerging-Smiths-Medical-integration
Adjusted EBITDA	~$355-440M	~15-17% margins Infusion-Therapy economics
Adjusted EPS	~$5.00-6.50	Multi-cycle-Infusion-Therapy-and-Smiths-Medical
Employee Count	~8,500+	San-Clemente-CA-HQ + Multi-Office-and-Manufacturing
Infusion-Therapy-and-IV-Solutions-and-Smiths-Medical-Critical-Care Revenue Share	~95-99%	Largest-business
Emerging-Other Revenue Share	~1-5%	Emerging-multi-cycle
Net Debt	~$1.30-1.55B	~3.0-4.0x leverage post-2022-Smiths-Medical-acquisition
Credit Rating	Ba2/BB+	Multi-cycle-emerging-IG
Dividend	None	Multi-cycle-disciplined-debt-paydown-focused
Buyback	None	Multi-cycle-disciplined-debt-paydown-focused
Shares Outstanding	~24-25M	Multi-cycle-leveraged

Market Evaluation

At ~$105-185 per share, equity value ~$2.5-4.5B, EV ~$3.8-6.0B, providing ~~16-30x EPS and ~~9-14x EV/EBITDA — typical-mid-cap-Medical-Devices multiple consistent with multi-cycle 1992-NASDAQ-ICU-Medical-IPO + 2017-Pfizer-Hospira-Infusion-Systems-acquisition + 2022-Smiths-Medical-acquired-from-Smiths-Group + emerging-multi-cycle US-and-international-Infusion-Therapy + emerging-IV-Solutions + emerging-Smiths-Medical-Critical-Care tailwinds.

Base case: Infusion-Therapy-and-IV-Solutions constructive + emerging-Smiths-Medical-integration + emerging-Critical-Care + multi-cycle-disciplined-debt-paydown + revenue $2.40-2.65B + adj. EBITDA $385-475M + adj. EPS $5.65-7.25 + ~5-15% return.

Bull case: Infusion-Therapy-and-IV-Solutions accelerates + emerging-Smiths-Medical-integration delivers-substantial-synergy + emerging-Critical-Care inflects + revenue $2.55-2.80B + adj. EBITDA $415-510M + adj. EPS $6.25-7.75 + selective-M&A + emerging-strategic-acquisition-target (Baxter-International + Becton-Dickinson + Medtronic + Boston-Scientific + Stryker + Edwards-Lifesciences + Abbott + Fresenius + Hologic + Teleflex + private-equity-Medical-Devices-Carlyle-Apollo-Bain-KKR-Blackstone-Genstar-THL-H-F-TPG-Veritas-Cinven-Charterhouse-Avista-Welsh-Carson-Linden interest) + re-rate 18-35x + 25-50%+ return + takeout-premium-upside.

Bear case: Infusion-Therapy stresses + emerging-Smiths-Medical-integration disappoints + adj. EPS $3.20-4.30 + de-rate 10-15x + flat-to-substantially-negative.

FY2026 turns on Infusion-Therapy-and-IV-Solutions + emerging-multi-cycle-Smiths-Medical-integration + emerging-multi-cycle-Critical-Care + multi-cycle-disciplined-debt-paydown + Vivek Jain-strategic-execution.

Word count: 2010 </parameter> </invoke>

[ICUI] ICU Medical Thesis 2026: An Infusion-Therapy + IV-Solutions + Smiths-Medical Compounder